Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors.

被引：0
|
作者：
Zhang, Xing
Wen, Xizhi
Chen, Guojuan
Zeng, Shan
Men, Lichuang
Wang, Hengbang
He, Shulan
Ma, Yuxiang
Pan, QiuZhong
Zhang, Yang
Peng, Ruiqing
Weng, Desheng
Liu, Wenqin
Zhang, Li
Liang, Zhiyan
Yang, Dajun
Zhai, Yifan
机构：
[1] Sun Yat Sen Univ, Melanoma & Sarcoma Med Oncol Unit, Canc Ctr, Guangzhou, Peoples R China
[2] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China
[3] Sun Yat Sen Univ, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[4] Ascentage Pharma Grp Inc, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11542
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
    Rasco, Drew W.
    Lakhani, Nehal J.
    Li, Yufeng
    Men, Lichuang
    Wang, Hengbang
    Ji, Jiao
    Tang, Yuefen
    Liang, Zhiyan
    Amaya, Alex
    Estkowski, Kathy
    Sun, Joan
    Huang, Yingjie
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas.
    Zhang, Xing
    Wen, Xizhi
    Yang, Chen
    Zeng, Shan
    Men, Lichuang
    Wang, Hengbang
    Ma, Yuxiang
    Zhang, Yang
    Peng, Ruiqing
    Weng, Desheng
    Zhang, Li
    Ji, Jiao
    Liu, Wenqin
    Liang, Zhiyan
    Huang, Yingjie
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.
    LoRusso, Patricia
    Gounder, Mrinal M.
    Patel, Manish R.
    Yamamoto, Noboru
    Bauer, Todd Michael
    Laurie, Scott
    Grempler, Rolf
    Davenport, Teffany
    Geng, Junxian
    Rohrbacher, Maren
    Lahmar, Mehdi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] A novel MDM2-p53 antagonist APG-115 induces p53-mediated apoptosis and enhances radiosensitivity in colorectal cancer
    Yi, Han-Jie
    Yan, Xiang-Lei
    Luo, Qiu-Yun
    Yuan, Luping
    Li, Baoxia
    Pan, Wentao
    Zhang, Lin
    Qiu, Miao-Zhen
    Wang, Guangfeng
    Zhai, Yifan
    Yang, Da-Jun
    CANCER RESEARCH, 2018, 78 (13)
  • [5] A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma
    Hanjie Yi
    Xianglei Yan
    Qiuyun Luo
    Luping Yuan
    Baoxia Li
    Wentao Pan
    Lin Zhang
    Haibo Chen
    Jing Wang
    Yubin Zhang
    Yifan Zhai
    Miao-Zhen Qiu
    Da-Jun Yang
    Journal of Experimental & Clinical Cancer Research, 37
  • [6] Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.
    McKean, Meredith
    Tolcher, Anthony W.
    Reeves, James Andrew
    Chmielowski, Bartosz
    Shaheen, Montaser F.
    Beck, Joseph Thaddeus
    Orloff, Marlana M.
    Somaiah, Neeta
    Van Tine, Brian Andrew
    Drabick, Joseph J.
    Spira, Alexander I.
    O'byrne, Kenneth
    Karapetis, Christos Stelios
    Foresto, Steven A.
    Movva, Sujana
    Martinez, Jose
    Li, Mingyu
    Winkler, Robert
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma
    Yi, Hanjie
    Yan, Xianglei
    Luo, Qiuyun
    Yuan, Luping
    Li, Baoxia
    Pan, Wentao
    Zhang, Lin
    Chen, Haibo
    Wang, Jing
    Zhang, Yubin
    Zhai, Yifan
    Qiu, Miao-Zhen
    Yang, Da-Jun
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
  • [8] A novel small molecule inhibitor of MDM2-p53 (APG-115) has antitumor activity in gastric adenocarcinoma
    Zhang, Lin
    Luo Qiuyun
    Yan Xianglei
    Wan, Xueping
    Yuan, Luping
    Zhang, Yuxing
    Zhou, Suna
    Pan, Wentao
    Pan, Mengxian
    Qiu, Miaozhen
    Mai, Shijuan
    Yang, Dajun
    CANCER RESEARCH, 2019, 79 (13)
  • [9] MDM2-p53 Inhibitor Alrizomadlin (APG-115) Enhances Antitumor Activity of Pomalidomide in Multiple Myeloma (MM)
    Wang, Guangfeng
    Liang, Eric
    Min, Ping
    Ge, Yangfeng
    Wu, Bingxing
    Yu, Huidan
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2022, 140 : 9953 - 9954
  • [10] Phase Ib study of a novel, small-molecule MDM2 inhibitor APG-115 combined with pembrolizumab in US patients with metastatic solid tumors.
    Tolcher, Anthony W.
    Karim, Raghad
    Tang, Yuefen
    Wang, Hengbang
    Ji, Jiao
    Chen, Jason
    Kaiser, Angela
    Sheladia, Piyush
    Ahmad, Mohammad
    Liang, Zhiyan
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345